These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 22386923)
1. Stage for stage comparison of recurrence patterns after definitive chemoradiotherapy or surgery for oesophageal carcinoma. Reid TD; Davies IL; Mason J; Roberts SA; Crosby TD; Lewis WG Clin Oncol (R Coll Radiol); 2012 Nov; 24(9):617-24. PubMed ID: 22386923 [TBL] [Abstract][Full Text] [Related]
2. Stage-for-stage comparison of definitive chemoradiotherapy, surgery alone and neoadjuvant chemotherapy for oesophageal carcinoma. Morgan MA; Lewis WG; Casbard A; Roberts SA; Adams R; Clark GW; Havard TJ; Crosby TD Br J Surg; 2009 Nov; 96(11):1300-7. PubMed ID: 19847875 [TBL] [Abstract][Full Text] [Related]
3. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Smit JK; Muijs CT; Burgerhof JG; Paardekooper G; Timmer PR; Muller K; Woutersen D; Mul VE; Beukema JC; Hospers GA; van Dijk BA; Langendijk JA; Plukker JT Ann Surg Oncol; 2013 Jun; 20(6):1985-92. PubMed ID: 23274534 [TBL] [Abstract][Full Text] [Related]
4. Definitive chemoradiation for locoregional recurrences of esophageal cancer after primary curative treatment. Jeene PM; Versteijne E; van Berge Henegouwen MI; Bergmann JJ; Geijsen ED; Muller K; van Laarhoven HW; Hulshof MC Dis Esophagus; 2017 Feb; 30(2):1-5. PubMed ID: 27766725 [TBL] [Abstract][Full Text] [Related]
5. Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Matsuda S; Tsubosa Y; Niihara M; Sato H; Takebayashi K; Kawamorita K; Mori K; Tsushima T; Yokota T; Ogawa H; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y Ann Surg Oncol; 2015; 22(6):1866-73. PubMed ID: 25564176 [TBL] [Abstract][Full Text] [Related]
6. Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Karran A; Blake P; Chan D; Reid TD; Davies IL; Kelly M; Roberts SA; Crosby T; Lewis WG Br J Surg; 2014 Apr; 101(5):502-10. PubMed ID: 24615406 [TBL] [Abstract][Full Text] [Related]
7. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Smit JK; Güler S; Beukema JC; Mul VE; Burgerhof JG; Hospers GA; Plukker JT Ann Surg Oncol; 2013 Nov; 20(12):4008-15. PubMed ID: 23838922 [TBL] [Abstract][Full Text] [Related]
8. Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. Hategan M; Cook N; Prewett S; Hindmarsh A; Qian W; Gilligan D Dis Esophagus; 2015 Oct; 28(7):612-8. PubMed ID: 24863560 [TBL] [Abstract][Full Text] [Related]
9. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. Robb WB; Messager M; Dahan L; Mornex F; Maillard E; D'Journo XB; Triboulet JP; Bedenne L; Seitz JF; Mariette C; ; ; ; ; Br J Surg; 2016 Jan; 103(1):117-25. PubMed ID: 26511668 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer : Outcomes and patterns of failure. Haefner MF; Lang K; Verma V; Koerber SA; Uhlmann L; Debus J; Sterzing F Strahlenther Onkol; 2018 Feb; 194(2):116-124. PubMed ID: 28916906 [TBL] [Abstract][Full Text] [Related]
11. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179 [TBL] [Abstract][Full Text] [Related]
12. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Crosby T; Hurt CN; Falk S; Gollins S; Staffurth J; Ray R; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G; Mukherjee S Br J Cancer; 2017 Mar; 116(6):709-716. PubMed ID: 28196063 [TBL] [Abstract][Full Text] [Related]
13. Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery? Tougeron D; Scotté M; Hamidou H; Di Fiore F; Paillot B; Michot F; Michel P J Surg Oncol; 2012 Jun; 105(8):761-6. PubMed ID: 22124932 [TBL] [Abstract][Full Text] [Related]
14. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Chao YK; Yeh CJ; Chang HK; Tseng CK; Chu YY; Hsieh MJ; Wu YC; Liu HP Ann Surg Oncol; 2011 Feb; 18(2):529-34. PubMed ID: 20697822 [TBL] [Abstract][Full Text] [Related]
15. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Yamamoto S; Ishihara R; Motoori M; Kawaguchi Y; Uedo N; Takeuchi Y; Higashino K; Yano M; Nakamura S; Iishi H Am J Gastroenterol; 2011 Jun; 106(6):1048-54. PubMed ID: 21343920 [TBL] [Abstract][Full Text] [Related]
16. [Definitive chemoradiotherapy for esophageal cancer: 66Gy versus 50Gy, a retrospective study]. Clavier JB; Antoni D; Atlani D; Ben Abdelghani M; Schumacher C; Salze P; Noël G Cancer Radiother; 2013 Jun; 17(3):221-8. PubMed ID: 23684111 [TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851 [TBL] [Abstract][Full Text] [Related]
18. Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus. Stahl M; Lehmann N; Walz MK; Stuschke M; Wilke H Eur J Cancer; 2012 Nov; 48(16):2977-82. PubMed ID: 22503151 [TBL] [Abstract][Full Text] [Related]
19. Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy. Chao YK; Chan SC; Liu YH; Chen HW; Wan YL; Chang HK; Fan KH; Liu HP Ann Surg; 2009 Mar; 249(3):392-6. PubMed ID: 19247024 [TBL] [Abstract][Full Text] [Related]
20. Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: results of a retrospective non-randomized study. Hsu FM; Lin CC; Lee JM; Chang YL; Hsu CH; Tsai YC; Lee YC; Cheng JC J Surg Oncol; 2008 Jul; 98(1):34-41. PubMed ID: 18449912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]